BNC210BNC210 Vials

Clinically significant anxiety disorders represent one of the most widespread health problems in the developed world. Historically, treatments for anxiety have been some of the most commercially successful products in the pharmaceutical industry. The global therapeutic market for the treatment of anxiety is projected to reach US$4.6 billion by 2020.

However, current treatments suffer from serious side effects including sedation, memory loss and addiction. Others are unsatisfactory for patients due to slow onset of action (weeks), or sexual dysfunction side-effects.

Bionomics has discovered a novel compound BNC210 that offers competitive advantages over existing treatments.


The BNC375 program is developing small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease (AD).  These molecules may be applicable to other neurodegenerative and psychiatric diseases where there is a need to restore memory function such as Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder (ADHD). Compounds produced in this program have been effective in several animal models of impaired learning and memory over a broad dose range, and have an excellent safety profile.

In June 2014 Bionomics entered into an exclusive Research Collaboration and License Agreement with Merck, known as MSD outside the United States and Canada, for the BNC375 program targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions.

Alzheimer's is the most common type of dementia and thought to be caused by damage to nerve cells in the brain. Symptoms are characterised by a decline in memory or other thinking skills; it affects a person's everyday activities and is fatal. One in nine Americans older than 65 years has Alzheimer's disease (5 million people). It is the 6th leading cause of death in the United States. By 2025 the number of Americans aged 65 and older with Alzheimer's is forcast to rise 40% to 7.1 million (2014 Alzheimer's disease, Alzheimer's Association). More than 332,000 Australians suffer from Alzheimer's disease.